NEWS AND ISSUE IN HIV AND AIDS IN CHILDREN
HIV/AIDS Groups in U.S. Appear Mostly Optimistic About New Domestic HIV Plan
“This is a cause to shout hallelujah,” says veteran HIV activist Jesse Milan. He’s talking about the newly announced Act Against AIDS initiative. The plan, spearheaded by the U.S. Centers for Disease Control and Prevention, will blanket the country in new HIV awareness ads and involve 14 key African-American groups in re-energizing the fight against HIV within the U.S. (after eight long, silent years). However, although many in the HIV community are thrilled with the new plan, others are more cautious with their praise. “All of these African-American groups, none of them have any capacity to deal with gay men,” points out Alexander Robinson, director of the National Black Justice Coalition. (Excerpt of article from the Windy City Times)
For much more info on the Act Against AIDS initiative, check out this overview from the U.S. Centers for Disease Control and Prevention.
Major Drug Firms Will Combine to Form a Single HIV Drug Company
GlaxoSmithKline and Pfizer, two major drug companies that produce 11 HIV meds between them, have decided to join forces on the HIV front. They’re forming a new company that will devote itself entirely to HIV, and will combine the two parent companies’ HIV marketing, distribution, research and drug pipelines. The new company won’t be named until the deal is completed near the end of the year. The list of HIV meds manufactured by Glaxo or Pfizer includes Combivir (AZT/3TC), Lexiva (fosamprenavir, Telzir) and Selzentry (maraviroc, Celsentri). (Article from The New York Times)
As Drug Companies Fund the Fight Against HIV, Who’s Watching the Drug Companies?
The decision of GlaxoSmithKline and Pfizer to merge their HIV operations (see story above) raises an important question: Who’s making sure that these pharmaceutical mammoths are acting in the best interests of people with HIV? Drug companies are the driving force behind the development of new treatments, but what happens when other ideas — say, better HIV prevention methods or cheaper meds — threaten their profit margins? In this interview, longtime HIV advocate Mike Barr offers some insight into the complicated relationship between the HIV community and HIV drug companies. (Article from Frontiers IN L.A.)
INDONESIA AIDS GLOBAL SITUATION
LINK AIDS IN INDONESIA
AIDS ON HEADLINES NEWSPAPPER
FIGHT AGAINTS AIDS, SAVE INDONESIAN CHILDRENS
Office ; JL Taman Bendungan Asahan 5 Jakarta Indonesia 10210
phone : 62(021) 70081995 – 5703646
email : email@example.com,
Editor in Chief :
Dr WIDODO JUDARWANTO
phone : 62(021) 70081995 – 62(021) 5703646, mobile : 0817171764
email : firstname.lastname@example.org
Copyright © 2009, Fight Against Aids, Save Indonesian Childrens Information Education Network. All rights reserved.